BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

PEP-Therapy S.A.S. is developing fusion peptides for cancer that block specific intracellular protein-protein interactions, which could be safer than broad inhibitors of the same proteins. The company's fusion peptides comprise an optimized cell-penetrating peptide that...
Items per page:
1 - 1 of 1